Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.57 |
| ▸ | PIK3R1 | P27986 | 8/20 | 0.57 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.57 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30230513 | 0.89 | PIK3CD (0.63) | PIK3CDPIK3CGPIK3R1PIK3CBPIK3CA | |
| SCHEMBL356154 | 0.89 | PIK3CD (0.63) | PIK3CDPIK3CGPIK3R1PIK3CBPIK3CA | |
| SCHEMBL357282 | 0.89 | PIK3CD (0.63) | PIK3CDPIK3CGPIK3R1PIK3CBPIK3CA | |
| SCHEMBL11901144 | 0.87 | PIK3CD (0.51) | PIK3CDPIK3CGPIK3R1PIK3CBPIK3CA | |
| SCHEMBL11901429 | 0.87 | PIK3CD (0.51) | PIK3CDPIK3CGPIK3R1PIK3CBPIK3CA | |
| SCHEMBL11901434 | 0.87 | PIK3CD (0.51) | PIK3CDPIK3CGPIK3R1PIK3CBPIK3CA | |
| SCHEMBL356167 | 0.85 | PIK3CD (0.76) | PIK3CDPIK3CGPIK3R1PIK3CBPIK3CA | |
| SCHEMBL14992028 | 0.84 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3R1PIK3CBPIK3CA | |
| SCHEMBL16677348 | 0.84 | PIK3CB (0.77) | PIK3CDPIK3CGPIK3R1PIK3CBPIK3CA | |
| SCHEMBL357118 | 0.84 | PIK3CB (0.77) | PIK3CDPIK3CGPIK3R1PIK3CBPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2365810-A2 | PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20110021541-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2011-01-27 | — | — | US | disclosed |
| US-20110021541-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2011-01-27 | — | — | US | disclosed |
| US-20110021541-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2011-01-27 | — | — | US | disclosed |
| EP-2220089-A2 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2010065923-A2 | PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2009064802-A2 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ELI LILLY & CO. (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064802-A2 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ELI LILLY & CO. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021541-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | PIK3CD, PI4KB, PI4KA | PIK3CD 1/4885PIK3CG 4/4885PIK3R1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.